Ariel Kredentser
Research Subjects
Ariel Kredentser has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Nizam
Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Brooklyn, NY, United States
16 shared publications - Alexander Krasnitz
Cold Spring Harbor Laboratory
16 shared publications - Arisa Kapedani
Northwell Health 3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York
16 shared publications - Brian Yueh
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
16 shared publications - Charlie Chung
Cold Spring Harbor Laboratory 4 Cold Spring Harbor
16 shared publications - Gary L. Goldberg
Northwell Health 3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York
16 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
EC PDOs display heterogeneous EGFR expression.
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
EC PDOs display heterogeneous EGFR expression.
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
IFNγ pretreatment enhances cancer–immune cell interactions. A, A schematic depicting the experimental flow of organoid–immune cell coculture. EC, endometrial cancer. B, Raw colocalization coefficient between PDOs and caspase-3/7 signal from vehicle- and IFNγ-treated group (no immune cells) at the end point (86 hours). C, Representative images of coculture using a HGEC PDO with or without IFNγ prestimulation and autologous PBMC, CD8, and CD4 T cells. Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. D, Colocalization of PDOs and immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). E, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. Ordinary one-way ANOVA (E) was used to calculate statistical significance (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
IFNγ pretreatment enhances cancer–immune cell interactions. A, A schematic depicting the experimental flow of organoid–immune cell coculture. EC, endometrial cancer. B, Raw colocalization coefficient between PDOs and caspase-3/7 signal from vehicle- and IFNγ-treated group (no immune cells) at the end point (86 hours). C, Representative images of coculture using a HGEC PDO with or without IFNγ prestimulation and autologous PBMC, CD8, and CD4 T cells. Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. D, Colocalization of PDOs and immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). E, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. Ordinary one-way ANOVA (E) was used to calculate statistical significance (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
CAR-T cells demonstrate target-dependent activity in endometrial organoid. A, Representative images of coculture using a normal and two HGEC PDOs (low and high EGFR) without immune cells, with untransduced CD8 T cells (mock), or EGFR-CAR-T cells (55). Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. B, Colocalization of the PDOs and corresponding immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of the PDO in the coculture measured by colocalization coefficient between the PDOs and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. D, A schematic depicting the utilization of autologous PDO–immune coculture system. MSI-H, microsatellite instability–high; MSS, microsatellite stability. Ordinary one-way ANOVA (C) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
CAR-T cells demonstrate target-dependent activity in endometrial organoid. A, Representative images of coculture using a normal and two HGEC PDOs (low and high EGFR) without immune cells, with untransduced CD8 T cells (mock), or EGFR-CAR-T cells (55). Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. B, Colocalization of the PDOs and corresponding immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of the PDO in the coculture measured by colocalization coefficient between the PDOs and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. D, A schematic depicting the utilization of autologous PDO–immune coculture system. MSI-H, microsatellite instability–high; MSS, microsatellite stability. Ordinary one-way ANOVA (C) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
IFNγ pre-treatment in HGEC PDOs enhances cancer-immune cell interactions in both allogeneic and autologous setting.
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
IFNγ pre-treatment in HGEC PDOs enhances cancer-immune cell interactions in both allogeneic and autologous setting.
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Endometrial tumor organoids display a heterogenic immunomodulatory gene expression.
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Endometrial tumor organoids display a heterogenic immunomodulatory gene expression.
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Sub-lethal Tazemetostat treatment induced histone modification associates to MHC expression in Arid1A mutant HGEC PDOs.
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Sub-lethal Tazemetostat treatment induced histone modification associates to MHC expression in Arid1A mutant HGEC PDOs.
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
The antigen presentation and processing are downregulated in HGEC organoids. A, RNA-based ancestry estimation of endometrial cancer (EC) PDOs used in the experiments (n = 50). B, RNA-based ancestry estimation of EC PDOs used in the experiments classified based on the tumor grade. C, Bar plot showing endometrial cancer patients’ microsatellite stability status (n = 50) and associated BMI (cancer; n = 50, benign; n = 8). MSI, microsatellite instability; MSS, microsatellite stability. D, Heatmap generated from RNA-seq data using paired EC PDO lines (low-grade; n = 4, high-grade; n = 7, normal; n = 11). E, Violin plots highlighting MHC-II genes from (D) in HGEC (top, red) and LGEC (bottom, blue) PDOs and their matched normal pairs. F, Steady-state MHC-I, -II genes and PD-L1 mRNA expression levels among matched normal and HGEC PDOs analyzed by RT-PCR (n = 10 for each). Each dot represents a relative mRNA quantity of a target gene normalized to a reference gene, HSP90A from individual PDO line. G, Mean fluorescent intensity (MFI) of immunomodulatory protein expression levels of EC PDOs at steady-state measured by flow cytometry. (normal; n = 7, high-grade; n = 9). Ordinary one-way ANOVA (F and G) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
The antigen presentation and processing are downregulated in HGEC organoids. A, RNA-based ancestry estimation of endometrial cancer (EC) PDOs used in the experiments (n = 50). B, RNA-based ancestry estimation of EC PDOs used in the experiments classified based on the tumor grade. C, Bar plot showing endometrial cancer patients’ microsatellite stability status (n = 50) and associated BMI (cancer; n = 50, benign; n = 8). MSI, microsatellite instability; MSS, microsatellite stability. D, Heatmap generated from RNA-seq data using paired EC PDO lines (low-grade; n = 4, high-grade; n = 7, normal; n = 11). E, Violin plots highlighting MHC-II genes from (D) in HGEC (top, red) and LGEC (bottom, blue) PDOs and their matched normal pairs. F, Steady-state MHC-I, -II genes and PD-L1 mRNA expression levels among matched normal and HGEC PDOs analyzed by RT-PCR (n = 10 for each). Each dot represents a relative mRNA quantity of a target gene normalized to a reference gene, HSP90A from individual PDO line. G, Mean fluorescent intensity (MFI) of immunomodulatory protein expression levels of EC PDOs at steady-state measured by flow cytometry. (normal; n = 7, high-grade; n = 9). Ordinary one-way ANOVA (F and G) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Organoid–NK cell coculture and autologous MMRp and MMRd organoid coculture validate our platform. A, Representative images of allogeneic NK cell coculture using a HGEC PDO line with or without IFNγ prestimulation. Red and green fluorescence represent HGEC PDOs and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. B, Colocalization of PDOs and immune cells over the time of imaging. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. D, Representative images of coculture using MMRd and MMRp HGEC PDOs and autologous PBMCs. Scale bar, 70 μm. E, Quantification of MHC-I, -II, and PD-L1 protein expression levels of the MMRd and MMRp HGEC PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. F, Colocalization of PDOs and immune cells at 14 hours of coculture period. G, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. H, Viability of the MMRp PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. Cas3, caspase-3. Ordinary one-way ANOVA (C, G, and H) and t test (F) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Organoid–NK cell coculture and autologous MMRp and MMRd organoid coculture validate our platform. A, Representative images of allogeneic NK cell coculture using a HGEC PDO line with or without IFNγ prestimulation. Red and green fluorescence represent HGEC PDOs and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. B, Colocalization of PDOs and immune cells over the time of imaging. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. D, Representative images of coculture using MMRd and MMRp HGEC PDOs and autologous PBMCs. Scale bar, 70 μm. E, Quantification of MHC-I, -II, and PD-L1 protein expression levels of the MMRd and MMRp HGEC PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. F, Colocalization of PDOs and immune cells at 14 hours of coculture period. G, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. H, Viability of the MMRp PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. Cas3, caspase-3. Ordinary one-way ANOVA (C, G, and H) and t test (F) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Bispecific TCE constructs facilitate cancer–immune cell interactions. A, Quantification of EpCAM protein expression levels of the MMRd and MMRp PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. B, Representative images of autologous coculture using the MMRd HGEC PDO line. Red and green fluorescence represent organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. C, Representative images of autologous cancer–immune cell coculture using the MMRp HGEC PDO line. Scale bar, 70 μm. D, Colocalization of the MMRd HGEC PDOs and immune cells at 7 hours of coculture period. E, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 hours coculture period. F, Colocalization of the MMRp HGEC PDOs and immune cells at 42 hours of coculture period. G, Viability of the MMRd organoid in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 46 hours coculture period. Cas3, caspase-3. t test (A) and ordinary one-way ANOVA (D–G) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Bispecific TCE constructs facilitate cancer–immune cell interactions. A, Quantification of EpCAM protein expression levels of the MMRd and MMRp PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. B, Representative images of autologous coculture using the MMRd HGEC PDO line. Red and green fluorescence represent organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. C, Representative images of autologous cancer–immune cell coculture using the MMRp HGEC PDO line. Scale bar, 70 μm. D, Colocalization of the MMRd HGEC PDOs and immune cells at 7 hours of coculture period. E, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 hours coculture period. F, Colocalization of the MMRp HGEC PDOs and immune cells at 42 hours of coculture period. G, Viability of the MMRd organoid in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 46 hours coculture period. Cas3, caspase-3. t test (A) and ordinary one-way ANOVA (D–G) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Structure of TwoGATETM T cell engager.
- 25 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
Structure of TwoGATETM T cell engager.